Francisco J. Esteva: The critical need for continued innovation in managing low-risk breast cancers effectively
Francisco J. Esteva, Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared on LinkedIn:
“Interesting analysis by Lajos Pusztai and colleagues: Most breast cancer deaths now occur in patients initially diagnosed with low-risk stage I/II disease. While improved therapies have significantly reduced mortality in high-risk cases, the cumulative impact of small risks in this large group highlights an emerging challenge.
New approaches, like ctDNA monitoring and better adherence to endocrine therapy, could help identify and address relapse risks without overtreatment, offering hope for reducing deaths in these early-stage cases.
This underscores the critical need for continued innovation in managing low-risk breast cancers effectively.”
Dr. Francisco Javier Esteva is the Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital and a Professor of Medicine at the Zucker School of Medicine. He also serves as the Director of Breast Cancer Translational Research at Northwell Health. Before joining Northwell, he was a Research Professor at the NYU School of Medicine and Vice President of Clinical Development at Cellectis. Dr. Esteva prioritizes patient-centered care by ensuring patients are fully informed about their pathology, staging, molecular tests, and treatment options, fostering collaborative decision-making.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023